ALL test with LOT rules and updated questions

What is the disease definition and natural history of acute lymphoblastic leukemia?

The supplied documents define acute lymphoblastic leukemia (ALL) as "A group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of differentiation" that "primarily affects the bone marrow and peripheral blood" although "the abnormal cells can infiltrate any organ or tissue." Pediatric disease burden is emphasized because ALL "accounts for 75% of all cases of childhood leukemia cases" and "The peak incidence occurs between 2 and 5 years of age," while adolescents and young adults (AYAs) are described as a "unique population" with "distinctive care needs, social risk factors, and disease behavior compared with other age groups." Clinical presentation may include "lymphadenopathy, hepatosplenomegaly, bone pain, fever and signs of hemorrhage," and some patients present with "life-threatening hemorrhage, infection, or respiratory distress." Relapse and progression patterns are addressed mainly for AYAs with relapsed/refractory disease, where patients "experience greater treatment resistance, higher rates of toxicity," and management includes "immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy," including management of "CNS relapse." Frontline survival-relevant milestones discussed include "first remission," where "Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy." The supplied documents describe acute lymphocytic/lymphoblastic leukemia (ALL) epidemiology, treatment response, relapse, and survival patterns in U.S. and adult populations, but they do not provide the WHO/ICC disease definition or classification framework, nor a full disease pathophysiology description. The NCI SEER data state that "Acute lymphocytic leukemia is most common in children, adolescents, and young adults, or those 15 to 39 years of age" and that it is "most frequently diagnosed among people aged <20." Adult disease-course information is provided for Philadelphia chromosome-negative B-cell ALL (Ph- B-ALL), where "nearly half of patients relapsed within 3 years, and only 49%-69% survived beyond 3 years," while induction regimens in adult ALL achieve "complete response rates that range from 60% to 90%." Relapse and remission milestones are also described for Ph-positive ALL, in which "most of these patients experienc[ed] disease relapse at a median of 58 days after the start of therapy," and the national U.S. 5-year relative survival for acute lymphocytic leukemia was reported as "73.2% (2016–2022)." The supplied documents describe pediatric acute lymphoblastic leukemia (ALL) epidemiology in the United States, but they do not provide the WHO or ICC classification framework, detailed disease pathophysiology, adult ALL natural history, relapse biology, or survival milestones as of 2026-09-21. The documents state that “Acute lymphoblastic leukemia (ALL) is the most prevalent cancer among children and adolescents in the United States” and that it represents “20% of all cancers diagnosed in persons aged” under 20 years, with “3,000 new cases each year.” They also report that “Overall incidence of pediatric ALL during 2001–2014 was 34.0 cases per 1 million persons,” that incidence “increased during 2001–2008 and remained stable during 2008–2014,” and that “Rates were highest in children aged 1–4 years (75.2 per 1 million).” The documents further note coding and disease-grouping definitions used for surveillance, including “International Classification of Diseases for Oncology, Third Edition codes 9728–9729, 9811–9818, and 9835–9837” and that ““ALL” in this study includes precursor cell leukemia and lymphoma.” The supplied document defines acute lymphoblastic leukemia (ALL) as "a common type of acute leukemia" and states that it "is essentially a malignant clonal proliferative disorder of hematopoietic stem cells." The document reports that "high-dose chemotherapy combined with allogeneic hematopoietic stem cell transplantation (allo-HSCT) has significantly improved patient survival and has become the most effective therapeutic strategy for ALL," but also notes that "relapse remains a major challenge after transplantation." Regarding natural history and relapse patterns, the text states that "Most relapses occur in the bone marrow, whereas extramedullary relapse is relatively uncommon," and describes a rare case of "uterine and ovarian relapse after allo-HSCT" confirmed by biopsy and treated with chemotherapy, radiotherapy, and CAR-T immunotherapy, resulting in "clinical remission." The documents do not provide WHO or ICC classification frameworks, pediatric-versus-adult disease course comparisons, detailed clinical presentation, or survival milestones as of 2026-09-21. The supplied document addresses a specific subtype of acute lymphoblastic leukemia rather than the full WHO/ICC disease definition and classification framework for ALL. It states that “ZNF384-rearranged (ZNF384-r) B-cell acute lymphoblastic leukemia (B-ALL) is a rare subtype” and describes molecular and immunophenotypic characteristics including “The most common fusion partners were EP300::ZNF384 (43.3%) and TCF3::ZNF384 (31.7%); 58.3% of patients harbored kinase/RAS pathway mutations.” The document also reports survival and relapse-related clinical milestones after allogeneic hematopoietic stem cell transplantation, including “3-year overall survival (OS), leukemia-free survival (LFS), cumulative incidence of relapse (CIR), and non-relapse mortality (NRM) were 81.9%, 78.7%, 10.0%, and 11.3%, respectively.” It further notes that “Molecular MRD positivity was not associated with inferior OS (83.3% vs 81.8%; P = 0.806), LFS (66.7% vs 80.5%; P = 0.516), or CIR (25.0% vs 7.3%; P = 0.255).” The supplied document addresses limited aspects of acute lymphoblastic leukemia (ALL) diagnosis and demographics, but it does not provide the WHO/ICC classification framework, disease natural history, progression, relapse patterns, or survival milestones in the United States as of 2026-09-21. The document states that "By immunophenotyping, 42 patients (56.0%) had precursor acute lymphoblastic leukemia (ALL), 32 (42.7%) had acute myeloid leukemia (AML), and 1 (1.3%) had Burkitt lymphoma/leukemia." It also reports that "Flow cytometric immunophenotyping provides diagnostic precision" and that "Morphology demonstrates high agreement with immunophenotyping in the diagnosis of acute leukemia." Age-related distribution was described in this cohort, where "children accounted for 69.8% of ALL-group cases, whereas 81.3% of AML cases were adults." The supplied documents describe ALL as a leukemia affecting both children and adults and outline major clinical domains including “Pathophysiology,” “Presentation,” “Prognosis,” and treatment phases such as “Induction Chemotherapy,” “Consolidation Therapy,” “Maintenance Therapy,” and “CNS Prophylaxis.” The pediatric PDQ document reports major long-term survival improvements in the United States, stating that “For ALL, the 5-year survival rate increased over the same time, from 60% to approximately 90% for children younger than 15 years, and from 28% to more than 75% for adolescents aged 15 to 19 years.” The documents also indicate that survivors may experience long-term treatment-related effects requiring monitoring. However, the supplied materials do not provide the current WHO or ICC classification framework for ALL, detailed disease-definition criteria, or a comprehensive description of progression and relapse biology across pediatric and adult populations.

OrphanetAmerican Society of HematologyHematology (Amsterdam, Netherlands)National Cancer Institute, Surveillance, Epidemiology, and End Results ProgramNational Cancer InstituteCDC / NCHSZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesTransplantation and cellular therapyThe Libyan journal of medicineOpen web

What is the incidence, prevalence, survival and mortality of ALL in the United States, stratified by age group and subtype (B-ALL, T-ALL, Ph-positive)?

In the United States, SEER reports that “The rate of new cases of acute lymphocytic leukemia was 1.9 per 100,000 men and women per year” and “The death rate was 0.4 per 100,000 men and women per year,” with “an estimated 126,118 people living with acute lymphocytic leukemia in the United States” in 2023. SEER also reports “5-YearRelative Survival: 73.2% (2016–2022),” and notes that “Acute lymphocytic leukemia is most frequently diagnosed among people aged <20” and “is most common in children, adolescents, and young adults, or those 15 to 39 years of age.” Orphanet states that ALL “accounts for 75% of all cases of childhood leukemia cases” and that “The peak incidence occurs between 2 and 5 years of age.” For biologic subtype stratification, the supplied documents only provide adult Philadelphia chromosome-negative B-cell ALL data, reporting that “only 49%-69% survived beyond 3 years” in chemotherapy studies and that blinatumomab “reduced the risk of death by 59% versus chemotherapy alone (HR 0.41).” The documents do not provide U.S.-specific incidence, prevalence, mortality, or survival estimates for T-cell ALL or Philadelphia chromosome-positive ALL. The supplied documents provide limited U.S. epidemiology and survival information for acute lymphoblastic leukemia (ALL), primarily for pediatric incidence and adult leukemia survival analyses. A CDC report states that "Acute lymphoblastic leukemia (ALL) is the most prevalent cancer among children and adolescents in the United States" and that it represents "3,000 new cases each year." It further reports that "Overall incidence of pediatric ALL during 2001–2014 was 34.0 cases per 1 million persons" and that incidence "was highest among Hispanics (42.9 per 1 million)." For adult populations, a population-based registry study analyzed "five-year net survival" for leukemia subtypes, including ALL, among adults aged 15–99 years, but the excerpt supplied does not include numeric ALL survival estimates. The provided documents do not contain U.S. prevalence estimates, mortality rates, or subtype-specific estimates for B-cell ALL, T-cell ALL, or Philadelphia chromosome-positive ALL. The supplied document discusses treatment response and limited survival information for adult acute lymphoblastic leukemia (ALL), particularly Philadelphia chromosome-positive (Ph-positive) ALL, but it does not provide U.S. incidence, prevalence, mortality, or age-stratified epidemiologic estimates across pediatric and adult populations. For adult ALL, the document states that "Current multiagent induction regimens result in complete response rates that range from 60% to 90%." For Ph-positive ALL, the document reports that "Responses were short lived, with most of these patients experiencing disease relapse at a median of 58 days after the start of therapy" and that remissions are "generally short with conventional ALL chemotherapy clinical trials." The supplied documents do not provide United States-specific estimates for incidence, prevalence, mortality, or subtype-stratified outcomes for acute lymphoblastic leukemia (ALL), including B-cell ALL, T-cell ALL, or Philadelphia chromosome-positive ALL. The only relevant information available is a World Health Organization indicator for childhood lymphoid leukaemia survival in multiple countries, reporting “Childhood cancer survival for lymphoid leukaemia, age-standardized 5-year net survival (%)” for patients aged less than 20 years. No United States observation is included in the supplied material.

National Cancer Institute, Surveillance, Epidemiology, and End Results ProgramOrphanetHematology (Amsterdam, Netherlands)CDC / NCHSNational Cancer InstituteWorld Health Organization

What are the clinically important immunophenotypic and molecular subtypes of ALL?

The documents identify clinically relevant lineage-based and molecularly defined subtypes of ALL, particularly B-cell acute lymphoblastic leukemia (B-ALL). They specifically describe “ZNF384-rearranged (ZNF384-r) B-cell acute lymphoblastic leukemia (B-ALL)” as “a rare subtype,” note fusion partners including “EP300::ZNF384” and “TCF3::ZNF384,” and report associated “kinase/RAS pathway mutations,” “IKZF1, ETV6, and KMT2A/D abnormalities,” and an immunophenotypic feature of “uniform CD33 expression” in some fusion groups. The documents also distinguish “Philadelphia (Ph) chromosome-negative B-cell acute lymphoblastic leukemia (B-ALL)” in adults as a treatment-linked subgroup, stating that “Blinatumomab is currently the only targeted agent approved for frontline treatment,” with additional mention of “inotuzumab (±blinatumomab) plus chemotherapy” and rituximab evaluation. However, the supplied documents do not comprehensively cover pediatric versus adult ALL classification, T-cell ALL subtypes, the broader immunophenotypic marker landscape, or the full range of cytogenetic and molecular abnormalities used in U.S. diagnosis, prognosis, and treatment segmentation as of 2026-09-21. The documents identify clinically relevant immunophenotypic lineage subtypes of ALL as B-cell and T-cell ALL in both children and adults. One study reported that “Of the acute lymphoblastic leukemia cases, 130 cases (79.3%) were B-cell type and 34 cases (20.7%) were T-cell type.” Immunophenotypic markers linked to diagnosis and subclassification included B-cell markers “CD19,CD22 and cytoplasmic CD79a” with frequent “CD10” expression, while “Cytoplasmic CD3 and CD5 were the most sensitive markers for diagnosis of T-acute lymphoblastic leukemia.” The ASH guideline additionally identified treatment-linked subgrouping by noting that recommendations addressed “ALL subsets (T-cell ALL)” and focused on “immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy.” The supplied documents do not provide specific ALL cytogenetic abnormalities, molecular alterations, or detailed prognostic stratification schemas for pediatric versus adult patients in the United States. The supplied document identifies clinically relevant lineage-based subgroups of ALL in adolescents and young adults as “B-cell or T-cell acute lymphoblastic leukemia (B-ALL/T-ALL)” and also references “T-cell acute lymphoblastic lymphoma (T-LBL/LLy).” The guideline further states that “higher-risk subsets” may influence decisions regarding allogeneic hematopoietic stem cell transplantation and that “targeted agents in frontline therapy is increasingly supported,” indicating treatment-linked risk stratification and molecularly targeted treatment approaches. However, the document does not provide specific immunophenotypic markers, cytogenetic abnormalities, molecular alterations, or named prognostic molecular/cytogenetic subtypes. The supplied document identifies immunophenotypic lineage distinctions in acute lymphoblastic leukemia (ALL), including “precursor acute lymphoblastic leukemia (ALL)” and references to aberrant antigen expression patterns relevant to lineage assignment. It reports that “Flow cytometry supports more precise lineage assignment, particularly in ambiguous cases and those with aberrant markers,” and gives examples including “CD19 positivity in AML and CD2/CD7 co-expression in AML profiles.” However, the documents do not provide the clinically relevant cytogenetic or molecular ALL subtypes, prognostic categories, or treatment-linked subgrouping used in the United States as of 2026-09-21. The supplied documents identify acute lymphoblastic leukemia (ALL) as including both pediatric and adult disease and indicate that diagnosis and management involve “cytogenetics and immunophenotyping,” but they do not provide a comprehensive listing of clinically relevant immunophenotypic, cytogenetic, or molecular ALL subtypes as of 2026-09-21. The documents do reference treatment-linked subgrouping for “Mature B-Cell ALL” and “Ph Chromosome–Positive ALL,” and distinguish the need for “Immunohistochemistry and Cytogenetics” in workup. However, the supplied material does not enumerate the full set of B-cell versus T-cell lineage definitions, immunophenotypic markers, cytogenetic abnormalities, molecular alterations, prognostic categories, or modern treatment-segmentation schemas requested in the question.

Transplantation and cellular therapyHematology (Amsterdam, Netherlands)WHOAmerican Society of HematologyThe Libyan journal of medicineOpen web

How is ALL diagnosed and what confirmatory workup is required?

The supplied document states that “Accurate diagnosis of acute leukemia (AL) is essential for management” and that “Morphological assessment is used in resource-limited settings, but interpretation can be challenging in ambiguous cases.” It also reports that “Flow cytometric immunophenotyping provides diagnostic precision” and that “Flow cytometry supports more precise lineage assignment, particularly in ambiguous cases and those with aberrant markers.” The document further describes that newly diagnosed patients “were evaluated using morphology and immunophenotyping,” and that immunophenotyping classified cases as “precursor acute lymphoblastic leukemia (ALL),” “acute myeloid leukemia (AML),” or “Burkitt lymphoma/leukemia.” However, the supplied material does not provide United States-specific recommendations as of 2026-09-21 regarding diagnostic criteria, confirmatory bone marrow workup, cytogenetic testing, molecular testing, or baseline staging workup for pediatric and adult ALL. The supplied document identifies acute lymphoblastic leukemia (ALL) as "A group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of differentiation" and states that it "primarily affects the bone marrow and peripheral blood" while abnormal cells "can infiltrate any organ or tissue." The document also describes common presenting manifestations including "lymphadenopathy, hepatosplenomegaly, bone pain, fever and signs of hemorrhage." However, the supplied material does not provide the recommended United States diagnostic criteria or confirmatory workup for pediatric or adult ALL, including bone marrow evaluation, flow cytometry, cytogenetic testing, molecular testing, or baseline staging assessments. The supplied document describes diagnostic approaches used for newly diagnosed acute lymphoblastic leukemia (ALL), including clinical assessment, hematology testing, bone marrow aspiration, morphology, and cytochemical analysis. It states that “Bone marrow aspiration was done at the time of diagnosis” and that cases “were diagnosed by standard morphology… & cytochemical methods.” The document also references prognostic relevance of “T immunophenotyping” and cytogenetic abnormalities such as “t(9;22) translocation,” but it does not provide detailed United States diagnostic criteria, confirmatory flow cytometry panels, cytogenetic or molecular testing standards, or a baseline staging workup for pediatric and adult ALL as of 2026-09-21. The supplied documents indicate that the diagnostic workup for acute lymphoblastic leukemia (ALL) includes laboratory studies, bone marrow aspiration and biopsy, histologic evaluation, immunohistochemistry and cytogenetics, radiologic studies, cardiac studies, and lumbar puncture evaluation. One document specifically identifies workup sections titled “Routine Laboratory Studies,” “Bone Marrow Aspiration and Biopsy,” “Histologic Features,” “Immunohistochemistry and Cytogenetics,” and “Lumbar Puncture,” but the provided excerpt does not include the detailed diagnostic criteria, immunophenotypic markers, cytogenetic abnormalities, molecular assays, or baseline staging recommendations requested. The provided excerpts therefore do not fully answer the question regarding confirmatory laboratory, pathology, flow cytometry, cytogenetic, and molecular assessments for pediatric and adult ALL as of 2026-09-21.

The Libyan journal of medicineOrphanetWHOOpen web

How is ALL risk-stratified at diagnosis, and which patient characteristics drive cohort segmentation and treatment eligibility (age, comorbidity, performance status, organ function)?

The supplied documents identify several factors used to define frontline ALL treatment cohorts in the United States, particularly in adolescents and young adults (AYAs) and adults with Philadelphia chromosome-negative B-cell ALL. Age-based cohorting is explicitly recognized because “treatment regimens can vary significantly depending on whether they receive care in a pediatric or in an adult setting,” and AYAs are described as “a unique population” with distinct “disease behavior compared with other age groups.” Minimal residual disease (MRD) status is repeatedly used for treatment stratification, including “MRD negative patients” receiving frontline consolidation and “patients in MRD-positive CR1.” Higher-risk disease biology and treatment response are also used to guide therapy, because “allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy.” The documents do not provide detailed U.S. diagnostic risk-stratification schemas, specific comorbidity or performance-status thresholds, or explicit organ function eligibility criteria as of 2026-09-21. The supplied document discusses measurable residual disease (MRD) and genomic features in a specific subgroup of B-cell acute lymphoblastic leukemia (B-ALL), namely ZNF384-rearranged B-ALL undergoing allogeneic hematopoietic stem cell transplantation. It states that "Pre-transplant MRD was assessed by MFC and RT-qPCR targeting ZNF384 fusion transcripts" and describes discordant MRD categories including "MFC-negative/molecular-positive (MFC-/Mol+) MRD." The document also identifies biologic characteristics used for subgroup analyses, including "kinase/RAS pathway mutations," "IKZF1, ETV6, and KMT2A/D abnormalities," fusion partners such as "EP300::ZNF384" and "TCF3::ZNF384," and diagnostic immunophenotyping findings including "uniform CD33 expression." The document does not provide comprehensive United States ALL diagnostic risk-stratification systems, pediatric versus adult cohort definitions, age-based treatment cohorts, comorbidity or performance status criteria, organ function requirements, or broader treatment eligibility criteria as of 2026-09-21. The supplied document discusses adult ALL induction therapy and identifies a biologic treatment cohort based on Philadelphia chromosome positivity (Ph-positive ALL). It states that “imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials” and that “If a suitable donor is available, allogeneic bone marrow transplant should be considered because remissions are generally short with conventional ALL chemotherapy clinical trials.” The document does not provide pediatric or adult diagnostic risk-stratification systems, minimal residual disease criteria, age-based cohorts, comorbidity or performance status criteria, organ function requirements, or broader treatment eligibility definitions. The supplied documents identify that pediatric ALL treatment and outcomes are discussed in U.S. National Cancer Institute guidance and that ALL classification and risk stratification are active topics in the literature, but they do not provide a complete description of the specific U.S. diagnostic risk-stratification systems, MRD-based categories, organ-function requirements, performance-status criteria, or treatment-eligibility definitions requested. The documents do indicate age-based cohorts in pediatric and adolescent ALL, including “children younger than 15 years” and “adolescents aged 15 to 19 years,” and they reference treatment distinctions such as “Treatment of the Younger Adult” and “Treatment of Ph Chromosome–Positive ALL.” The provided excerpts do not contain detailed criteria for minimal residual disease status, comorbidity assessment, performance status, organ function thresholds, or formal cohort eligibility rules as of 2026-09-21.

American Society of HematologyHematology (Amsterdam, Netherlands)Transplantation and cellular therapyNational Cancer InstituteOpen web

What are the current guideline-recommended first-line regimens for ALL, by treatment setting (induction, consolidation, maintenance, MRD-positive) and guideline preference category (e.g., NCCN Preferred / Other Recommended / Useful in Certain Circumstances)?

The supplied documents identify major U.S. guideline bodies and versions for Acute Lymphoblastic Leukemia (ALL), including the NCCN adult ALL guideline Version 2.2024, the NCCN Pediatric ALL guideline Version 2.2025, and the American Society of Hematology (ASH) 2026 guideline for frontline management of ALL in adolescents and young adults (AYAs). The NCCN adult guideline states that it focuses on “treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence,” and describes “treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients.” The pediatric NCCN guideline states that it focuses on “risk assessment and stratification of risk-adapted therapy” and “treatment strategies for BCR::ABL1 (Philadelphia chromosome [Ph])-negative and BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL.” The ASH 2026 guideline states that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” and that “Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy.” However, the supplied documents do not provide the specific first-line induction, consolidation, maintenance, or MRD-positive regimens, nor do they provide detailed guideline preference categories or regimen-level recommendations by subgroup. The supplied documents identify major guideline bodies and some high-level frontline management recommendations for acute lymphoblastic leukemia (ALL), but they do not provide the detailed first-line treatment regimens across induction, consolidation, maintenance, and MRD-positive settings requested in the question. The 2026 ASH guideline for adolescents and young adults (AYAs) states that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” and that “Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy.” The NCCN pediatric ALL guideline (Version 2.2020) states that it “provide[s] recommendations on the workup, diagnostic evaluation, and treatment of the disease,” while the NCCN ALL guideline notes that recommendations are “based on the Philadelphia chromosome status and age (adults vs. adolescents/young adults), assessment of minimal residual disease, and supportive care considerations.” However, the documents do not enumerate specific induction, consolidation, maintenance, or MRD-positive regimens, nor do they specify guideline preference categories or detailed subgroup-specific regimen listings. The supplied documents do not provide a comprehensive account of United States first-line Acute Lymphoblastic Leukemia (ALL) guideline regimens across induction, consolidation, maintenance, and MRD-positive settings, nor do they provide guideline preference categories or detailed subgroup-based first-line recommendations. One document describes a clinical trial in newly diagnosed Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-like) B-ALL using “blinatumomab with dasatinib or imatinib and standard chemotherapy,” and specifies prior induction components including “vinCRIStine, a corticosteroid, pegaspargase or calaspargase pegol, with or without anthracycline, and/or other standard cytotoxic chemotherapy.” Another document summarizes 2026 ASH guidelines for “relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults,” stating that recommendations covered “remission reinduction and consolidation” and included “the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction,” but it does not address first-line therapy or maintenance regimens. The supplied document does not provide major U.S. clinical guideline recommendations, guideline versions, preference categories, or comprehensive first-line regimens across induction, consolidation, maintenance, and MRD-positive settings for Acute Lymphoblastic Leukemia as of 2026-09-21. It does report an FDA approval relevant to newly diagnosed Philadelphia chromosome-positive ALL in adults: “On March 19, 2024, the Food and Drug Administration granted accelerated approval to ponatinib (Iclusig, Takeda Pharmaceuticals U.S.A., Inc.) with chemotherapy for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).” The document describes the chemotherapy backbone as “3 cycles of induction with vincristine and dexamethasone, 6 cycles of consolidation alternating between methotrexate and cytarabine, and 11 cycles of maintenance with vincristine and prednisone,” and states that “The ponatinib dose was reduced to 15 mg once daily after completion of the induction phase and achievement of minimal residual disease (MRD)-negative complete remission (CR).” The supplied documents do not provide a comprehensive list of first-line treatment regimens for Acute Lymphoblastic Leukemia (ALL) across induction, consolidation, maintenance, and MRD-positive settings, nor do they provide detailed guideline preference categories or subgroup-specific regimen tables. The documents do identify two guideline-related recommendations: the 2026 American Society of Hematology (ASH) guideline for adolescents and young adults (AYAs) with relapsed/refractory ALL states that “Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction,” and addresses “the role of consolidation with allogeneic transplant.” A separate ASCO-published report states that “guidelines from the National Comprehensive Cancer Network now recommend consideration of pediatric inspired treatment” for AYAs with ALL. No document supplies complete first-line induction, consolidation, maintenance, or MRD-positive regimen algorithms, preference levels, or full patient/disease subgroup categorizations. The supplied documents do not provide a comprehensive account of United States major clinical guideline recommendations as of 2026-09-21 for first-line Acute Lymphoblastic Leukemia (ALL) regimens across induction, consolidation, maintenance, and MRD-positive settings, nor do they provide guideline preference categories or detailed subgroup stratification. The documents do provide limited information that the NCCN Guidelines for ALL include recommendations on treatment approaches and that adult ALL induction commonly uses combination chemotherapy with prednisone, vincristine, and an anthracycline, with some regimens adding asparaginase or cyclophosphamide. The NCI PDQ document also states that imatinib is generally incorporated for Ph-positive ALL and that allogeneic bone marrow transplant should be considered when a suitable donor is available because remissions are short with conventional chemotherapy. The supplied documents identify only limited guideline information relevant to frontline ALL treatment recommendations in the United States as of 2026-09-21. The American Society of Hematology published “American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults,” specifically addressing “frontline management of ALL in AYAs,” and noting that “treatment regimens can vary significantly depending on whether they receive care in a pediatric or in an adult setting.” A Medscape summary updated March 17, 2026 describes the standard treatment phases for B-cell ALL as “a pretreatment phase,” followed by “an induction phase,” “a consolidation phase,” and then “maintenance therapy or allogeneic hematopoietic stem cell transplantation (HSCT),” and states that treatment decisions are influenced by subgroup factors including “Age,” “Philadelphia chromosome (Ph)( BCR::ABL1_) status,” “Cell origin (B-cell vs T-cell),” and “Minimal residual disease (MRD) status.” However, the provided documents do not supply the requested detailed first-line regimens, guideline preference categories, or explicit MRD-positive regimen recommendations across induction, consolidation, maintenance, and MRD-positive settings.

Journal of the National Comprehensive Cancer Network : JNCCNBlood advancesAmerican Society of HematologyNational Cancer Institute (NCI)FDAJournal of Clinical OncologyNational Cancer InstituteZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiOpen web

What are the guideline-recommended regimens for later-line, relapsed, or refractory ALL, by treatment setting and guideline preference category?

The supplied documents identify that major guidelines addressing relapsed/refractory ALL in the United States include the 2026 ASH guidelines for adolescents and young adults (AYAs) with relapsed/refractory ALL and the NCCN ALL guidelines, but the excerpts provided do not contain detailed regimen tables stratified by treatment setting, line of therapy, biomarker subgroup, or guideline preference category. The ASH guideline states that its recommendations cover “remission reinduction and consolidation” and focus on “immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy.” The ASH guideline further reports that “Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction,” and that “Additional management of ALL subsets (T-cell ALL), CNS relapse, and the role of consolidation with allogeneic transplant are addressed.” The NCCN excerpt confirms that the NCCN Guidelines provide recommendations for “treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL” and classification based on “immunophenotype and cytogenetic/molecular markers,” but the supplied text does not provide later-line regimen lists or preference categories. The supplied documents discuss investigational and salvage approaches for relapsed/refractory acute lymphoblastic leukemia (ALL), including chemotherapy, CAR-T therapy, and allogeneic stem cell transplantation, but they do not provide U.S. major clinical guideline recommendations, preferred categories, or regimen stratification by line of therapy and biomarker subgroup. One study states that in relapsed or refractory adult ALL, “Salvage regimens in these patients and in patients with primary refractory disease are generally based on cytarabine in combination with other agents,” and evaluated “Cytarabine 100 mg/m 2 continuous infusion for seven days along with idarubicin 12 mg/m 2 day 1 to 3, IV bolus.” The documents also describe CD19-targeted CAR-T therapy in “CD19+ R/R B-ALL” and compare CAR-T with HSCT, noting that “Patients who had a relapse after CAR-T received HSCT and relapse after HSCT received CAR-T as an option, both led to better clinical outcomes.” However, the documents do not identify guideline bodies, recommendation categories, later-line sequencing recommendations, or formal transplant/cell-therapy guidance frameworks. The supplied documents do not provide a comprehensive United States guideline-based listing of recommended regimens for relapsed, refractory, and later-line Acute Lymphoblastic Leukemia stratified by treatment setting, line of therapy, biomarker subgroup, and guideline preference category. The documents do contain limited treatment recommendations and descriptions relevant to relapsed/refractory ALL. One evidence-based review states that for pediatric ALL, "Allogeneic SCT is recommended for children who: are in second complete remission (CR2) after experiencing an early marrow relapse for precursor-B ALL; experienced primary induction failure, but subsequently achieved a CR1; have T-lineage ALL in CR2; or have ALL in third or greater remission." Another study in relapsed/refractory T-ALL/LBL reports use of several venetoclax-containing later-line regimens, including "Ven monotherapy," "Ven + hypomethylating agent," "Ven + chemotherapy," "Ven + nelarabine," "Ven + targeted agent," and "Ven + navitoclax," and notes that "21% of pts proceeded to allo-HCT after ven-based therapy." The supplied documents do not provide a comprehensive list of major U.S. clinical guideline-recommended regimens for relapsed, refractory, and later-line Acute Lymphoblastic Leukemia stratified by treatment setting, line of therapy, biomarker subgroup, and guideline preference category. The documents do contain limited information about relapsed/refractory (R/R) ALL biomarker-defined populations and prior therapy considerations in a revumenib study, including "Documented R/R ALL/MPAL with KMT2A rearrangement" and timing requirements after stem cell transplant and CAR-T or other modified cell therapy. The documents also discuss Philadelphia chromosome-positive (Ph+) ALL and tyrosine kinase inhibitors (TKIs), stating that "Targeting of BCR-ABL with tyrosine kinase inhibitors (TKIs) has resulted in rapid clinical responses in the vast majority of patients with CML and Philadelphia chromosome+ ALL." No document provides NCCN/ASCO/ESMO regimen preference categories, later-line regimen tables, or transplant recommendations organized by line of therapy. The supplied documents do not provide a comprehensive listing of United States major clinical guideline regimens, preference categories, or line-specific recommendations for relapsed, refractory, and later-line acute lymphoblastic leukemia as of 2026-09-21. The documents do contain limited information that CAR-T cells are used in relapsed/refractory B-cell acute lymphoblastic leukemia in children, adolescents, and young adults, including discussion of bridging therapy before CAR-T reinfusion and situations involving “relapsed or refractory B-ALL, Ph+/ABL-like B-ALL and in case of CNS disease or non-CNS extra medullary disease.” One document also identifies venetoclax and bortezomib in relapsed/refractory early T-cell precursor acute lymphoblastic leukemia, and another identifies retreatment with inotuzumab ozogamicin for relapsed/refractory Philadelphia chromosome–negative B-cell acute lymphoblastic leukemia, but no guideline preference categories or detailed regimen stratifications are provided. The supplied documents do not provide a comprehensive list of United States major clinical guideline recommendations for relapsed, refractory, and later-line Acute Lymphoblastic Leukemia (ALL) stratified by treatment setting, line of therapy, biomarker subgroup, and guideline preference category. The documents do contain limited information relevant to relapsed/refractory T-cell ALL/T-cell lymphoblastic lymphoma (T-ALL/T-LBL), including an FDA-labeled later-line indication for nelarabine after at least two prior chemotherapy regimens, and investigational CD7 CAR-T therapy with subsequent stem cell transplantation in some patients. One ASH guideline document discusses frontline management and states that allogeneic hematopoietic stem cell transplantation “is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy,” but it does not address relapsed/refractory or later-line guideline categories. The supplied documents do not contain major clinical guideline recommendations, guideline preference categories, treatment-setting stratification, later-line regimen sequencing, biomarker subgroup guidance beyond Philadelphia chromosome positivity, or recommendations regarding cell therapy or transplant use for relapsed/refractory Acute Lymphoblastic Leukemia. The documents do contain FDA labeling information indicating that dasatinib is indicated for “Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy,” and for “newly diagnosed Ph+ ALL in combination with chemotherapy” in pediatric patients. The documents also identify ponatinib (ICLUSIG) and dasatinib (SPRYCEL/Dasatinib tablets) FDA applications/products, but they do not provide clinical guideline preference categories or regimen recommendations. The supplied documents do not provide "major clinical guidelines" recommendations, guideline preference categories, or a comprehensive stratification by treatment setting, line of therapy, biomarker subgroup, and later-line use for Acute Lymphoblastic Leukemia as of 2026-09-21 in the United States. The documents do contain limited information about therapies studied or compared in relapsed/refractory ALL, including CD19-directed CAR-T therapy, tisagenlecleucel, blinatumomab, clofarabine-based regimens, and investigational venetoclax-containing therapy for T-ALL/T-LLy. They also reference transplant and cell therapy use, including that tisagenlecleucel was evaluated "with use as a bridge to transplant" and that patients in a T-ALL/T-LLy study "must have had at least 30 days between prior hematopoietic stem cell transplant and first dose of study drug." The supplied documents identify that NCCN guidelines address relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL), including targeted agents, tyrosine kinase inhibitors, and allogeneic hematopoietic cell transplantation, but they do not provide the specific recommended regimens, later-line sequencing, biomarker-stratified regimens, or preference categories requested. The documents state that recommendations are stratified by factors including Philadelphia chromosome/BCR::ABL1 status, age group, and lineage subtype, and that the pediatric guidelines address “BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL.” Cell therapy/transplant use is referenced through “allogeneic hematopoietic cell transplantation,” but no detailed transplant indications or CAR-T recommendations are provided in the supplied text. The supplied documents do not provide a comprehensive summary of United States major clinical guideline recommendations for relapsed, refractory, and later-line Acute Lymphoblastic Leukemia (ALL) stratified by treatment setting, line of therapy, biomarker subgroup, guideline preference category, or detailed use of cell therapy. One document references treatment agents in relapsed or refractory ALL, specifically “blinatumomab” and “inotuzumab ozogamicin” in adults “receiving zero or one prior salvage therapy.” Another guideline-oriented document discusses frontline management in adolescents and young adults and states that “Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy.” The supplied documents do not provide major clinical guideline recommendations, preference categories, treatment-setting stratification, later-line regimens, cell therapy, or transplant guidance for acute lymphoblastic leukemia as of 2026-09-21 in the United States. The documents only provide FDA labeling indications for tyrosine kinase inhibitors in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Specifically, dasatinib is indicated for “adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy,” and imatinib mesylate is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).” The supplied documents do not provide major clinical guideline recommendations, stratification by treatment setting, biomarker subgroup, guideline preference category, cell therapy, or transplant use for relapsed, refractory, and later-line Acute Lymphoblastic Leukemia (ALL). The documents only describe FDA labeling for clofarabine in pediatric relapsed or refractory ALL after at least two prior regimens. Specifically, clofarabine injection is indicated for “pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens,” which identifies a later-line relapsed/refractory setting in pediatric ALL. The supplied document does not provide major clinical guideline recommendations, treatment stratification by line of therapy, biomarker subgroup, or guideline preference category for relapsed, refractory, or later-line Acute Lymphoblastic Leukemia (ALL). It does provide FDA information confirming that TECARTUS (brexucabtagene autoleucel), a cell therapy, is indicated in the United States for “Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).” No transplant recommendations, later-line regimen listings, NCCN/ASCO/ESMO preference categories, or biomarker-specific regimen guidance are included in the provided material. The documents do state that imatinib is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).” Another supplied document identifies a study regimen for relapsed and refractory ALL in adults: “Fludarabine, cytarabine, and mitoxantrone (FLAM).”

Journal of the National Comprehensive Cancer Network : JNCCNBlood advancesJournal of Clinical OncologyBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationSyndax PharmaceuticalsThe Journal of molecular diagnostics : JMDJCO Precision OncologyBulletin du cancerAlembic Pharmaceuticals LimitedAmerican Society of HematologyTAKEDA PHARMS USABluePoint LaboratoriesM.D. Anderson Cancer CenterUS Food and Drug AdministrationApotex CorpSun Pharmaceutical Industries, Inc.Amneal Pharmaceuticals LLCDr.Reddy's Laboratories IncFDA

Which therapies are FDA-approved (or otherwise officially approved) for ALL, with label indication, approved line, biomarker restriction, and approval date?

The supplied documents identify FDA-approved kinase inhibitors for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): imatinib mesylate (Gleevec/imatinib) and dasatinib. Imatinib mesylate is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and for “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.” Dasatinib is indicated for “Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy” in adults and for “pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.” Biomarker restriction in all ALL indications identified is Philadelphia chromosome-positive (Ph+); approval timing information in the documents includes “Initial U.S. Approval: 2001” for imatinib mesylate and “Initial U.S. Approval: 2006” for dasatinib, and the Gleevec NDA record lists “Application: NDA021588 sponsored by NOVARTIS” with product strengths “EQ 100MG BASE” and “EQ 400MG BASE.” The documents do not provide a complete list of all FDA-approved ALL drugs, biologics, cellular therapies, or claims-analytics coding identifiers such as HCPCS, CPT, NDC, or J-codes. The supplied documents identify several FDA-approved drugs for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), but they do not provide a complete United States ALL treatment landscape as of 2026-09-21, and they do not provide claims-analytics coding identifiers. Imatinib mesylate is labeled for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and for “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.” Dasatinib (SPRYCEL) is indicated for “adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.” The ICLUSIG (ponatinib) document confirms the FDA application and multiple efficacy and labeling supplements for NDA203469 but does not include the ALL indication text in the supplied excerpt. The documents consistently restrict the ALL indications to “Philadelphia chromosome positive (Ph+)” disease, but they do not provide HCPCS, NDC, J-codes, ICD-10, or other claims-relevant coding identifiers. The documents identify two FDA-approved drugs for Acute Lymphoblastic Leukemia (ALL): nelarabine and clofarabine. Nelarabine injection is approved for "T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens," and its label states "Initial U.S. Approval: 2005." Clofarabine injection is approved for "pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens," with "Initial U.S. Approval: 2004," and one label specifies that "This indication is based upon response rate" and that "There are no trials verifying an improvement in disease-related symptoms or increased survival with clofarabine injection." The supplied documents do not provide claims-analytics coding identifiers, HCPCS, NDC summaries, biologics, CAR-T or other cellular therapies, or additional officially authorized ALL therapies. The supplied document discusses management recommendations for relapsed/refractory acute lymphoblastic leukemia (ALL) in adolescents and young adults, including the use of certain immunotherapies and targeted therapies, but it does not provide a comprehensive list of FDA-approved or officially authorized drugs, biologics, or cellular therapies in the United States as of 2026-09-21. The document specifically states that the guideline recommendations “focused on the following treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy,” and that “Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction.” The document does not provide FDA approval dates, labeled indications, biomarker restrictions, treatment lines beyond relapsed/refractory reinduction context, or claims-relevant coding identifiers. The supplied documents discuss investigational and commercial-use contexts for tisagenlecleucel (CTL019) and investigational CD19 CAR-T therapies in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), but they do not provide a complete list of FDA-approved or officially authorized U.S. therapies for Acute Lymphoblastic Leukemia as of 2026-09-21. The documents identify tisagenlecleucel use in patients with relapsed/refractory B-cell acute lymphoblastic leukemia and refer to treatment "within the approved label" in another jurisdiction, but they do not provide U.S. FDA approval dates, labeled treatment lines, claims-relevant coding identifiers, or comprehensive biomarker restrictions. The documents also describe investigational CD19-targeted CAR-T therapies such as obe-cel in pediatric relapsed/refractory B-ALL, including CD19-expression requirements, but these are presented as clinical studies rather than FDA approvals. The supplied documents identify three FDA-approved drugs for Acute Lymphoblastic Leukemia (ALL): clofarabine injection, mercaptopurine oral suspension, and methotrexate injection. Clofarabine injection is indicated in a relapsed/refractory pediatric setting after at least two prior regimens; mercaptopurine is indicated as part of a combination chemotherapy maintenance regimen; and methotrexate injection is indicated as part of a combination chemotherapy regimen for adult and pediatric ALL patients. Biomarker-related restrictions are only described for mercaptopurine, where TPMT and NUDT15 deficiency are addressed through dosage modifications. The documents provide Initial U.S. Approval dates for these products (1953 for mercaptopurine and methotrexate; 2004 for clofarabine), but they do not provide claims-relevant coding identifiers or a comprehensive list of all FDA-authorized biologics or cellular therapies for ALL. The supplied documents identify two FDA-labeled drug products with indications involving acute lymphoblastic leukemia (ALL): imatinib mesylate and methotrexate tablets. Methotrexate tablets are indicated for the “treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.” The documents do not provide FDA approval dates, biologics or cellular therapies for ALL, or claims-relevant coding identifiers such as HCPCS, NDC, CPT, or ICD codes. The documents identify several FDA-regulated products associated with Acute Lymphoblastic Leukemia (ALL), but they do not provide a complete list of all FDA-approved or authorized drugs, biologics, and cellular therapies for ALL as of 2026-09-21, nor do they provide comprehensive claims analytics coding identifiers. Methotrexate Injection is labeled for “treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen,” and the label states “Initial U.S. Approval: 1953.” ARRANON (nelarabine) and SPRYCEL (dasatinib) are identified in FDA Drugs@FDA records with NDA numbers and approval/submission histories, including original approval dates of “2005-10-28” for ARRANON and “2006-06-28” for SPRYCEL, but the supplied documents do not include their ALL indication language, treatment line, biomarker restrictions, or claims-relevant coding identifiers. The supplied documents do not provide a comprehensive list of FDA-approved or officially authorized drugs, biologics, and cellular therapies for Acute Lymphoblastic Leukemia (ALL) in the United States as of 2026-09-21, and they do not provide claims-relevant coding identifiers. The documents do identify several therapies discussed in relapsed/refractory ALL guidance, including “blinatumomab” and “inotuzumab,” and describe that “targeted agents” and “tyrosine kinase inhibitors” are part of treatment recommendations. One FDA labeling document states that “DOXOrubicin HCl Injection, USP and DOXOrubicin HCl for Injection, USP have been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia,” but it does not provide an ALL-specific FDA approval date, treatment line, biomarker restriction, or claims analytics code. The supplied documents discuss several therapies used or studied in acute lymphoblastic leukemia (ALL), including rituximab, inotuzumab ozogamicin, blinatumomab, and autologous CAR-T-cell therapies, particularly in relapsed/refractory settings and pediatric B-ALL. However, the documents do not provide a comprehensive list of FDA-approved or officially authorized products in the United States as of 2026-09-21, and they do not provide approval dates, labeled indications, treatment lines, biomarker restrictions, or claims-related coding identifiers. The documents specifically describe inotuzumab ozogamicin as producing responses in relapsed/refractory ALL, blinatumomab as active in minimal residual disease and relapsed/refractory settings, and CAR-T-cell therapy as a major modality in relapsed/refractory B-cell ALL in children, adolescents, and young adults. The supplied documents identify two FDA-labeled drugs for Acute Lymphoblastic Leukemia (ALL): methotrexate and doxorubicin hydrochloride. Methotrexate tablets are indicated for “treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen,” which specifies a maintenance treatment setting and includes both adult and pediatric patients, with no biomarker restriction stated in the labeling excerpts provided. Doxorubicin Hydrochloride Injection is indicated “for the treatment of • acute lymphoblastic leukemia,” but the provided text does not specify treatment line, setting, or biomarker restrictions for ALL. The documents do not provide FDA approval dates, HCPCS/NDC/J-codes, billing identifiers, or cellular therapies/biologics officially authorized for ALL. The supplied documents discuss clinical guidelines and recommendations for acute lymphoblastic leukemia (ALL), including frontline management strategies, but they do not provide a complete list of FDA-approved or officially authorized drugs, biologics, or cellular therapies for ALL in the United States as of 2026-09-21. The documents also do not provide approval dates, labeled indications, treatment-line specifications, biomarker restrictions for specific FDA-approved products, or claims-relevant coding identifiers. The documents do state that recommendations are based on factors such as “Philadelphia chromosome status and age” and mention that “targeted agents in frontline therapy is increasingly supported,” but no product-specific regulatory approvals or coding data are included. The supplied documents discuss investigational and comparator therapies in Acute Lymphoblastic Leukemia (ALL), including blinatumomab, dasatinib, imatinib, venetoclax, and MK-1045, but they do not provide a complete list of FDA-approved or officially authorized drugs, biologics, or cellular therapies for ALL in the United States as of 2026-09-21. The documents also do not provide FDA approval dates, labeled indications, claims-related coding identifiers, or comprehensive approved treatment lines/settings. They do contain disease-setting and biomarker details for clinical trial populations, including Philadelphia chromosome positive (Ph+), ABL-class Philadelphia chromosome-like (Ph-like), CD19-positive, Philadelphia-negative, and KMT2A-rearranged ALL populations. The supplied document discusses asparaginase-containing regimens for acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL) and states that "The results of these studies have informed updates to the National Comprehensive Cancer Network guidelines and 2024 European LeukemiaNet recommendations for ALL management, which now advocate for PIRs in AYAs and adults with ALL/LBL." The document does not provide a comprehensive list of FDA-approved or officially authorized drugs, biologics, or cellular therapies for ALL in the United States as of 2026-09-21, and it does not provide labeled indications, approval dates, biomarker restrictions, treatment-line specifications, or claims-relevant coding identifiers. One document describes an interventional study of blinatumomab in newly diagnosed Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia, specifically in adults who are in complete remission or complete remission with incomplete peripheral count recovery after induction. The study compares subcutaneous versus continuous intravenous blinatumomab used with chemotherapy. The supplied documents identify doxorubicin (Adriamycin doxorubicin hcl) as an FDA-labeled treatment for acute lymphoblastic leukemia (ALL). The labeling states that “Doxorubicin is indicated for the treatment of acute lymphoblastic leukemia,” and provides dosing for “Metastatic Disease, Leukemia, or Lymphoma” including both single-agent and combination-therapy settings. The documents do not provide FDA approval dates, biomarker restrictions, treatment-line specifications for ALL, cellular therapies, biologics, or claims-relevant coding identifiers such as HCPCS, CPT, NDC, or ICD codes.

Apotex CorpBluePoint LaboratoriesNOVARTISTAKEDA PHARMS USASun Pharmaceutical Industries, Inc.US Food and Drug AdministrationAlembic Pharmaceuticals LimitedAmneal Pharmaceuticals LLCAmerican Society of HematologyMemorial Sloan Kettering Cancer CenterAutolus LimitedNovartis PharmaceuticalsDr.Reddy's Laboratories IncHikma Pharmaceuticals USA Inc.Hospira, Inc.Alembic Pharmaceuticals Inc.Aurobindo Pharma LimitedSANDOZBRISTOL MYERS SQUIBBBlood advancesJournal of the National Comprehensive Cancer Network : JNCCNAmerican Society of Clinical Oncology Educational BookBulletin du cancerBryant Ranch PrepackPfizer Laboratories Div Pfizer IncNational Cancer Institute (NCI)Merck Sharp & Dohme LLCAmerican journal of hematologyAmgen

How does ALL treatment differ between Ph-positive and Ph-negative disease and by other biomarker or risk segments, and at what point in the journey is biomarker testing expected (at diagnosis vs. at progression)?

The documents describe treatment pathway differences for adult Philadelphia chromosome (Ph)-positive ALL versus general adult ALL induction therapy, and they also describe biomarker-driven monitoring after CD19 CAR T-cell therapy in pediatric and young adult B-ALL. For adult ALL, "Most current induction regimens for patients with adult ALL include combination chemotherapy with prednisone, vincristine, and an anthracycline," while for "newly diagnosed adult patients with Ph-positive ALL" the "inclusion of imatinib into a relatively standard chemotherapy regimen" is described as potentially providing "a significant survival advantage," and "allogeneic bone marrow transplant should be considered because remissions are generally short with conventional ALL chemotherapy clinical trials." The documents also define MRD- and biomarker-based eligibility and monitoring after CAR T therapy, including that participants "are flow cytometry measurable residual disease (MRD) negative within 42 days post CD19 CART infusion" and "Are NGS MRD negative by tracking sample in the bone marrow within 42 days post CD19 CART infusion," with serial blood and bone marrow testing performed "every 2 weeks starting 42 days after they receive CART therapy" and at "routine timepoints after CART." The supplied documents do not provide a complete guideline-level description of ALL treatment pathways by all requested risk segments, age groups, molecular biomarkers, or comprehensive biomarker-testing schedules across the full treatment journey. The supplied documents address adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) and indicate that treatment pathways differ by treatment setting, response quality, relapse status, and certain disease subsets, but they do not provide a complete stratified pathway by Philadelphia chromosome status, molecular biomarkers, MRD status, or biomarker-testing timepoints. For frontline AYA ALL, the guidelines state that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” and that “Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy.” The documents also note that “The use of targeted agents in frontline therapy is increasingly supported,” while relapsed/refractory guidance recommends “the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction” and addresses “Additional management of ALL subsets (T-cell ALL), CNS relapse, and the role of consolidation with allogeneic transplant.” The documents do not specify biomarker testing schedules or explicit treatment differences by Philadelphia chromosome positivity/negativity, MRD category, or named molecular biomarkers. The supplied document does not provide U.S. guideline-recommended Acute Lymphoblastic Leukemia treatment pathways by Philadelphia chromosome status, MRD status, age group, or broader risk stratification. It does describe a high-risk subgroup, stating that “Philadelphia (Ph)-like acute lymphoblastic leukemia (ALL) is a high-risk subgroup of B-ALL associated with high rates of chemotherapy resistance and relapse” and that Ph-like ALL “is defined by an activated cytokine receptor and kinase signaling profile similar to that of Philadelphia chromosome-positive (Ph+) ALL yet lacking BCR-ABL1 rearrangement.” The document also identifies biomarker-driven testing and treatment selection around CRLF2/TSLPR status, noting that “Most CRLF2-rearranged (CRLF2-R) Ph-like ALL cases can be readily identified by increased TSLPR surface expression by flow cytometric immunophenotyping, and specific CRLF2 rearrangements can then be confirmed by genetic testing,” and eligibility for the investigational pathway required “TSLPR+ expression” and “any evidence of MRD.” The treatment pathway described is investigational CAR-T therapy for relapsed or refractory disease, where participants “will receive LD preparative regimen of fludarabine and cyclophosphamide followed by an infusion of TSLPR-CART.” The supplied documents indicate that Acute Lymphoblastic Leukemia (ALL) treatment and outcomes are discussed in relation to Philadelphia chromosome status, including “Philadelphia chromosome-associated acute lymphoblastic leukemia (Ph+ ALL)” and “adult acute lymphoblastic leukemia based on Philadelphia chromosome status.” One document also references “BCR-ABL mutation status” in “imatinib-resistant patients,” implying molecular biomarker evaluation in Ph+ ALL contexts. However, the documents do not provide guideline-recommended treatment pathways, MRD-based stratification, age-group-specific pathways, biomarker testing timepoints, or other risk-segment treatment differences. The supplied document does not describe guideline-recommended Acute Lymphoblastic Leukemia treatment pathways by Philadelphia chromosome status, molecular biomarkers, MRD status, age group, or broader risk stratification in the United States as of 2026-09-21. It only addresses venous thromboembolism management in children with ALL and identifies certain high-risk subgroups during induction, including “T-cell ALL, adolescents older than 10years, overweight patients.” The document also states that inherited thrombophilia testing is not routinely recommended and, when indicated, should be performed “outside periods of asparaginase exposure.” The documents state that ALL treatment pathways differ by age group, Philadelphia chromosome status, cytogenetic and molecular risk factors, CD20 expression, cell origin, and MRD status. Treatment decisions are described as being influenced by “Age,” “Philadelphia chromosome (Ph)( BCR::ABL1_) status and other cytogenetic factors,” “Presence of CD20-positive disease,” “Cell origin (B-cell vs T-cell),” and “Minimal residual disease (MRD) status.” NCCN risk stratification cited in the document categorizes several biomarkers as standard risk, including “t(9;22)(q34;q11.2): BCR::ABL1_ without IKZF1_ and without antecedent chronic myeloid leukemia (CML),” while poor-risk disease includes “BCR::ABL1_-like ALL,” “IKZF1 alterations,” “TP53 mutation,” “KMT2A rearranged,” and “t(9:22)(q34:q110: BCR::ABL1_ with IKZAF_ plus and/or antecedent CML.” The treatment journey is described as including “a pretreatment phase,” “an induction phase,” “a consolidation phase,” and follow-up with “maintenance therapy or allogeneic hematopoietic stem cell transplantation (HSCT),” but the supplied documents do not specify detailed biomarker-testing timepoints within these phases.

National Cancer InstituteNational Cancer Institute (NCI)American Society of HematologyJournal of Clinical OncologyBulletin du cancerOpen web

What recent FDA approvals or label expansions have occurred in ALL?

The supplied documents provide limited information on FDA actions related to Acute Lymphoblastic Leukemia (ALL) therapies. Dasatinib labeling states that it is indicated for “adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy” and for “pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.” Nelarabine labeling states that it is indicated for “T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.” The GLEEVEC record lists multiple FDA supplement approval dates, including “SUPPL 63 AP 2024-03-01,” but the supplied text does not specify whether these supplements involved ALL indications, label expansions, or treatment-setting changes. The supplied FDA Drugs@FDA records show several recent FDA supplemental approvals, efficacy supplements, and labeling actions for therapies associated with Acute Lymphoblastic Leukemia, but they do not describe the affected patient populations, supplemental indications, or treatment settings in detail. For SPRYCEL (NDA021986), recent actions included “SUPPL 28 AP 2024-07-31 Labeling STANDARD,” “SUPPL 27 AP 2023-02-08 Labeling STANDARD,” and an earlier “SUPPL 21 AP 2018-12-21 Efficacy PRIORITY.” For ICLUSIG (NDA203469), recent actions included “SUPPL 34 AP 2020-12-18 Efficacy PRIORITY,” “SUPPL 33 AP 2020-07-10 Labeling STANDARD,” and “SUPPL 38 AP 2025-10-10 Efficacy STANDARD.” For ARRANON (NDA021877), the record lists “SUPPL 14 AP 2025-03-11 Labeling STANDARD” and “SUPPL 10 AP 2019-07-31 Efficacy STANDARD.” The documents do not specify the exact ALL indications, label expansions, patient subgroups, or new treatment settings tied to these actions. The supplied documents do not describe recent FDA approvals, supplemental indications, label expansions, or newly approved treatment settings for Acute Lymphoblastic Leukemia therapies through 2026-09-21. They only provide existing labeled indications and initial U.S. approval information for imatinib mesylate and dasatinib. The documents state that imatinib mesylate is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and for “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy,” with “Initial U.S. Approval: 2001.” The dasatinib label states that SPRYCEL is indicated for “adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy,” with “Initial U.S. Approval: 2006.” The provided document identifies existing FDA-labeled indications for imatinib mesylate in Acute Lymphoblastic Leukemia (ALL), including “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.” However, the document does not provide recent FDA approval dates, supplemental indication dates, label expansion dates, or new treatment-setting approvals through 2026-09-21. The supplied document reports an FDA approval related to IMKELDI. It states that NDA219097 for "IMKELDI SOLUTION ORAL strength EQ 80MG BASE/ML" received an approval on "2024-11-22" as a "Type 3 - New Dosage Form STANDARD" application sponsored by SHORLA ONCOLOGY. The document does not state that this therapy is for Acute Lymphoblastic Leukemia, and it does not provide any affected patient population, supplemental indication, label expansion, or treatment setting information.

BluePoint LaboratoriesNOVARTISAlembic Pharmaceuticals LimitedBRISTOL MYERS SQUIBBTAKEDA PHARMS USASANDOZApotex CorpSun Pharmaceutical Industries, Inc.US Food and Drug AdministrationSHORLA ONCOLOGY

Which approvals or indications in ALL have been withdrawn or restricted (e.g., accelerated-approval withdrawals), and on what dates?

The supplied documents do not identify any Acute Lymphoblastic Leukemia drug or biologic approvals or indications that were explicitly withdrawn, restricted, suspended, or materially revised. One document lists regulatory submission and approval dates for ICLUSIG (ponatinib), including labeling and efficacy supplements through 2025, but it does not describe the scope of any withdrawn or restricted ALL indication. Another document describes clofarabine’s indication for relapsed or refractory ALL and states that the indication is "based upon response rate" with "no trials verifying an improvement in disease-related symptoms or increased survival," but it does not state that any approval or indication was withdrawn or revised. The supplied document identifies the FDA approval history for ARRANON (nelarabine), an Acute Lymphoblastic Leukemia therapy, including the original approval and later supplements, but it does not describe any withdrawn indications, restricted approvals, suspended approvals, or accelerated approval withdrawals or revisions. The document shows that ARRANON NDA021877 received its original FDA approval on 2005-10-28 and includes later labeling and efficacy supplements through 2025-03-11.

TAKEDA PHARMS USAUS Food and Drug AdministrationSANDOZ

Which products are used off-label or are compendia-supported for ALL, by line of therapy, and what codes represent each?

The documents describe therapies used in adult and pediatric acute lymphoblastic leukemia (ALL) across induction, maintenance, and Philadelphia chromosome positive (Ph+ ALL) settings, but they do not provide billing codes, HCPCS/NDC product codes, or explicit major drug compendia listings. For remission induction in adult ALL, the NCI PDQ states that "Most current induction regimens for patients with adult ALL include combination chemotherapy with prednisone, vincristine, and an anthracycline," and that some regimens "also add other drugs, such as asparaginase or cyclophosphamide." The same source states that "Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials," including in "newly diagnosed adult patients with Ph-positive ALL." FDA labeling documents show that methotrexate is indicated for "acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen," while imatinib is labeled for "Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)" and for "Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy." The documents describe investigational or off-label use of several therapies in Acute Lymphoblastic Leukemia (ALL), including venetoclax, blinatumomab, and daratumumab-hyaluronidase, but they do not provide major drug compendia support status, billing codes, HCPCS/J-codes, NDCs, or other product codes for claims-based analysis. In the newly diagnosed infant ALL setting, a phase II trial evaluated “the addition of venetoclax and/or blinatumomab to usual chemotherapy” in “infants with newly diagnosed acute lymphoblastic leukemia (ALL)” including KMT2A-rearranged and KMT2A-germline disease, with venetoclax used during induction and blinatumomab used in a “BLINATUMOMAB BLOCK 1.” In a relapsed or refractory minimal residual disease setting, daratumumab-hyaluronidase was studied for “persistent or recurrent MRD following treatment with chemotherapy” in T-cell ALL patients who were “in first or later hematologic CR or CRi after a minimum of 2 blocks of intensive chemotherapy.” The supplied documents do not identify lines of therapy using standardized commercial terminology, do not mention treatment-setting reimbursement classifications, and do not include any billing or product coding information. The supplied documents provide guideline-supported treatment recommendations and settings for acute lymphoblastic leukemia (ALL), including newly diagnosed adult Ph-negative ALL, pediatric ALL, and relapsed/refractory ALL in adolescents and young adults (AYAs). The NCCN adult ALL guideline "focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence," while the pediatric NCCN guideline focuses on "treatment strategies for BCR::ABL1 (Philadelphia chromosome [Ph])-negative and BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL." The ASH 2026 guideline for relapsed/refractory AYA ALL states that key recommendations "include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction" and that recommendations addressed "immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy." The documents do not provide billing codes, HCPCS/J-codes, NDCs, product codes, explicit off-label designations, or detailed claims-analysis coding information by line of therapy. The supplied documents identify some labeled therapies and mention NCCN guideline coverage for pediatric acute lymphoblastic leukemia (ALL), including frontline and relapsed/refractory settings, but they do not provide billing codes, product codes, or a comprehensive list of off-label or compendia-supported therapies by line of therapy and treatment setting. Imatinib mesylate is labeled for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and for “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.” Mercaptopurine is labeled “for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.” The NCCN pediatric ALL guideline document states that it “focuses on the frontline and relapsed/refractory management of pediatric ALL,” but the excerpt does not enumerate therapies, lines of therapy, compendia support categories, or claims-analysis coding information. The supplied documents describe some therapies and treatment settings for acute lymphoblastic leukemia (ALL), including frontline and resistant/intolerant Philadelphia chromosome-positive (Ph+) ALL settings, but they do not provide billing codes, HCPCS/CPT codes, NDCs, or other claims-analysis product codes. The ASH 2026 guideline states that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” and that “The use of targeted agents in frontline therapy is increasingly supported.” The dasatinib label states that dasatinib is indicated for “Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy” and for “pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.” The NCCN guideline excerpt states that recommendations include “risk-stratified treatment approaches based on the Philadelphia chromosome status and age (adults vs. adolescents/young adults).” The documents identify therapies used in relapsed/refractory acute lymphoblastic leukemia (ALL) settings and specify prior-line requirements for some products, but they do not provide billing codes, HCPCS codes, NDCs, or other claims-analysis product codes. Nelarabine is indicated in the relapsed/refractory setting for “T-cell acute lymphoblastic leukemia (T-ALL)” after “at least two chemotherapy regimens,” and clofarabine is indicated for pediatric relapsed/refractory ALL after “at least two prior regimens.” An ASH guideline for adolescents and young adults with relapsed/refractory ALL states that recommendations “include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction,” and that the guideline addresses “T-cell ALL,” “CNS relapse,” and “the role of consolidation with allogeneic transplant.” The supplied documents do not explicitly identify therapies as “off-label” or “supported by major drug compendia,” and they do not include treatment billing or product coding information. The supplied documents identify several therapies used in Acute Lymphoblastic Leukemia (ALL), including Philadelphia chromosome-positive ALL and relapsed/refractory ALL, but they do not provide major drug compendia support details or any billing/product codes for claims-based analysis. Dasatinib (SPRYCEL) is described for “adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy,” indicating a relapsed/refractory treatment setting after prior therapy. Blinatumomab was studied in pediatric “relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL)” including patients with “refractory, ≥ 2 relapses or relapse after transplant hct,” corresponding to later-line/high-risk treatment settings. ICLUSIG (ponatinib) product information is listed, but the supplied text does not state ALL indications, line of therapy, treatment setting, compendia support, or billing/product codes. The supplied documents identify therapies and treatment settings for Acute Lymphoblastic Leukemia (ALL), but they do not provide billing codes, HCPCS/J-codes, NDC product codes, or explicit claims-analysis coding guidance. Imatinib mesylate is described for ALL in specific settings: “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.” The NCCN Guidelines Insights document discusses treatment recommendations and settings for ALL, including “relapsed or refractory (R/R) ALL,” and notes use of “more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation,” but it does not identify billing codes or explicitly label therapies as off-label or compendia-supported. The supplied documents discuss several therapies used in Acute Lymphoblastic Leukemia (ALL), including CD19 CAR therapy and asparaginase-based regimens, but they do not provide major drug compendia listings, explicit off-label classifications, line-of-therapy categorizations, treatment-setting mappings, or billing/product codes for claims-based analysis. One document states that “CD19 CAR therapy” has shown “remarkable clinical outcomes in adults and children with ALL” and may “become part of the armamentarium for B cell-ALL,” indicating use in B-cell ALL across heavily pretreated populations. Another document describes “asparaginase-containing regimens” and “pediatric/pediatric-inspired regimens incorporating asparaginase for treating adolescent and young adult (AYA) and adult populations with acute lymphoblastic leukemia/lymphoblastic lymphoma,” but without coding or reimbursement information. The supplied documents identify clofarabine as an FDA-labeled therapy for a relapsed/refractory acute lymphoblastic leukemia setting in pediatric patients after at least two prior regimens, which corresponds to a later-line therapy setting rather than frontline use. The documents also include ASH 2026 frontline management guidance for adolescents and young adults with ALL, stating that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” and that “The use of targeted agents in frontline therapy is increasingly supported.” However, the documents do not provide specific off-label therapies, compendia-supported uses, billing codes, HCPCS/CPT/J-codes, NDCs, or other product codes for claims-based analysis. The supplied documents identify methotrexate as a therapy used for Acute Lymphoblastic Leukemia (ALL) in a defined treatment context: "treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen." The documents also identify ARRANON as an FDA-listed injectable intravenous product, but they do not state its ALL indication, line of therapy, treatment setting, compendia-supported use, off-label use, or any billing or claims-analysis codes. None of the supplied documents provide information about major drug compendia support, off-label ALL therapies, treatment-line categorization, treatment settings beyond maintenance regimen language, or billing/product codes such as HCPCS, CPT, NDC mappings, or revenue codes. The supplied documents identify FDA-labeled therapies for Acute Lymphoblastic Leukemia (ALL), but they do not provide information on off-label therapies, compendia-supported uses, line of therapy, treatment settings, or billing/product codes for claims-based analysis. Methotrexate Injection is described as indicated for “treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen,” and the dosage section states that “Methotrexate Injection is used as part of a multi-drug regimen.” The SPRYCEL document lists oral tablet product strengths and regulatory submission history, but it does not describe ALL treatment lines, settings, compendia support, off-label use, or claims codes. The supplied document provides treatment regimens and treatment phases for adult acute lymphoblastic leukemia (ALL), including induction, consolidation/post-remission, and maintenance therapy, but it does not identify United States-specific off-label uses, major drug compendia support, or billing/product codes for claims-based analysis. The document describes induction regimens such as VDP, VIP, VD(C)LP, Hyper-CVAD, CD20 monoclonal antibody combinations, and post-remission use of CD19/CD3 bispecific antibody therapy (blinatumomab), including settings such as younger adults, older adults, MRD-positive disease, consolidation, and transplant bridging. No HCPCS, NDC, CPT, revenue, billing, or product codes are provided. The supplied documents identify doxorubicin (including Adriamycin formulations) as a therapy indicated for Acute Lymphoblastic Leukemia (ALL). The documents state that “Doxorubicin Hydrochloride Injection is indicated for the treatment of • acute lymphoblastic leukemia” and similarly that “Doxorubicin is indicated for the treatment of acute lymphoblastic leukemia.” However, the documents do not provide information about off-label use, compendia-supported use, line of therapy, treatment settings, or billing/product codes for claims-based analysis. Therefore, only the existence of an FDA-labeled ALL indication for doxorubicin can be confirmed from the supplied evidence. The documents identify several therapies used or studied in Acute Lymphoblastic Leukemia (ALL), including rituximab, inotuzumab ozogamicin, blinatumomab, and autologous chimeric antigen receptor cells. The treatment settings explicitly described include relapsed/refractory ALL, minimal residual disease, and newly diagnosed ALL, but the documents do not provide explicit line-of-therapy categorizations, compendia-supported indications, or U.S. billing/product codes for claims-based analysis. One document discusses the broader topic of off-label oncology drug use and drug compendia, but it does not provide ALL-specific therapies or coding details in the supplied text.

National Cancer InstituteAlembic Pharmaceuticals Inc.US Food and Drug AdministrationNational Cancer Institute (NCI)Eastern Cooperative Oncology GroupJournal of the National Comprehensive Cancer Network : JNCCNBlood advancesApotex CorpHikma Pharmaceuticals USA Inc.American Society of HematologyBluePoint LaboratoriesAlembic Pharmaceuticals LimitedAmneal Pharmaceuticals LLCTAKEDA PHARMS USAJournal of Clinical OncologySun Pharmaceutical Industries, Inc.American Society of Clinical Oncology Educational BookAmerican journal of hematologyDefault Digital Object GroupDr.Reddy's Laboratories IncSANDOZAurobindo Pharma LimitedBryant Ranch PrepackBRISTOL MYERS SQUIBBHospira, Inc.Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiPfizer Laboratories Div Pfizer IncJournal of Oncology Practice

How have guideline recommendations for ALL changed over the study period, and on what dates?

The supplied documents describe 2026 American Society of Hematology (ASH) guideline recommendations for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL), including frontline and relapsed/refractory management, but they do not provide a longitudinal chronology of guideline evolution, regimen removals, or reclassification history across multiple years. The 2026 frontline guideline states that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” and that “The use of targeted agents in frontline therapy is increasingly supported.” The 2026 relapsed/refractory guideline highlights biomarker- and immunotherapy-oriented treatment changes, including “the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction,” with focus on “immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy.” The documents indicate that the evidence reviews supporting these recommendations included “systematic evidence reviews up to November 2023,” but they do not specify additional effective dates, regimen removals, or preference-category reclassifications. The supplied document describes contemporaneous treatment approaches for adult Acute Lymphoblastic Leukemia (ALL) but does not provide a chronology of guideline evolution, update dates, regimen removals, or reclassification history through 2026-09-21. It states that "Most current induction regimens for patients with adult ALL include combination chemotherapy with prednisone, vincristine, and an anthracycline" and that some regimens "also add other drugs, such as asparaginase or cyclophosphamide." The document also describes a biomarker-driven change for Philadelphia chromosome–positive (Ph-positive) ALL, noting that "inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a significant survival advantage" and that "Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials." The supplied documents describe guideline and treatment recommendation updates for ALL through 2026, but they do not provide a complete longitudinal chronology of additions, removals, or regimen preference reclassifications across all major U.S. guidelines. In February 2026, ASH published new clinical practice guidelines for adolescents and young adults with ALL, including recommendations favoring “Pediatric-inspired regimens over traditional adult-inspired protocols,” emphasizing “Asparaginase as a cornerstone of therapy,” and calling for “Re-evaluation of allogeneic transplant in first remission given insufficient evidence to support its routine use.” The same ASH release stated that relapsed/refractory recommendations included “Immunotherapy over traditional chemotherapy approaches,” support for “Allogeneic transplant in patients who achieve remission but with individualized assessment,” and “Intrathecal chemotherapy for isolated central nervous system relapse.” A March 17, 2026 Medscape summary citing NCCN-described risk factors documented biomarker-driven stratification including “_BCR::ABL1_ without _IKZF1_” as standard risk and “_BCR::ABL1_-like ALL,” “_IKZF1_ alterations,” and other molecular abnormalities as poor risk, while also stating that “BCR-ABL TKIs are the backbone of care in Ph-positive B-cell ALL” and that second- or third-generation TKIs are preferred over “the first-generation TKI imatinib.”

American Society of HematologyNational Cancer InstituteOpen web

What are the published benchmarks for time on treatment, time to next treatment, and PFS (progression-free survival) in ALL by line and key regimen?

The supplied literature is a 2026 ASH guideline for frontline management of acute lymphoblastic leukemia in adolescents and young adults (AYAs), and it does not provide published benchmarks for time on treatment, time to next treatment, progression-free survival, or other line-specific survival metrics by regimen or subgroup. The document does identify frontline treatment approaches and subgroup context, stating that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols” and that “Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy.” The guideline also specifies that it applies to “AYAs with B-cell or T-cell acute lymphoblastic leukemia (B-ALL/T-ALL) or T-cell acute lymphoblastic lymphoma (T-LBL/LLy) receiving frontline therapy.” The supplied literature provides only limited benchmark-style outcome data for adult and relapsed/refractory acute lymphoblastic leukemia (ALL). In newly diagnosed adult ALL, the NCI PDQ states that “Current multiagent induction regimens result in complete response rates that range from 60% to 90%,” and for Philadelphia chromosome–positive (Ph-positive) ALL treated with imatinib-containing approaches, “most of these patients experiencing disease relapse at a median of 58 days after the start of therapy” with “a median duration of 2.2 months.” The ASH 2026 guideline for adolescents and young adults (AYAs) with relapsed/refractory ALL discusses treatment approaches by subgroup and modality, including “blinatumomab and/or inotuzumab over chemotherapy for reinduction,” but the provided text does not report numerical benchmarks for time on treatment, time to next treatment, progression-free survival, or line-specific survival outcomes. The supplied literature does not provide published benchmarks for time on treatment, time to next treatment, progression-free survival, or line-specific outcomes by regimen and subgroup in Acute Lymphoblastic Leukemia. The document instead describes a biomarker-guided post-CAR-T monitoring study in pediatric and young adult relapsed B-ALL, and reports only limited remission-related outcome context. Specifically, it states that after CAR-T therapy, remission “may cure up to 50% of people who receive this therapy,” while also noting “dismal outcomes for patients who experience a relapse following CD19 CART.” The study focus is on “improving overall survival” and “improve LFS post CD19 CART” through biomarker-guided monitoring and potential transplant consolidation, but no numerical benchmarks for progression-free survival, time on treatment, or time to next treatment are reported. The document instead describes eligibility, follow-up duration, and general response observations for a first-in-human CAR T-cell trial in recurrent or refractory CRLF2/TSLPR-overexpressing B-ALL. It notes that CD19-directed CAR T-cell therapies produced “dramatic responses in >70% of patients with relapsed/refractory B-ALL,” and that “up to 50% of those who achieve remission will subsequently relapse,” but no formal progression-free survival, treatment duration, or time-to-next-treatment benchmarks are reported by line of therapy, regimen, or subgroup.

American Society of HematologyNational Cancer InstituteBlood advancesNational Cancer Institute (NCI)

What proportion of ALL patients advance from 1L to 2L, 3L, and beyond, and what drives attrition between lines?

The supplied document discusses relapsed B-cell acute lymphoblastic leukemia (B-ALL) populations receiving CD19 CAR T-cell therapy and subsequent consideration of hematopoietic cell transplantation (HCT), but it does not report quantitative line-of-therapy advancement rates or proportions of patients moving from first-line to later-line therapy. The document does identify relapse after CAR T-cell therapy as a major driver for subsequent treatment escalation, stating that “for people who relapse after CART, it can be hard to achieve remission again” and that “In patients where CART fails, stem cell transplant (HCT) can be used to prevent relapse and achieve cure.” Mortality and outcome concerns are also described as attrition-related factors, including “the dismal outcomes for patients who experience a relapse following CD19 CART” and the need “to improve overall survival.” Clinical and treatment-related factors affecting continuation or transition of therapy include measurable residual disease (MRD), persistence of B-cell aplasia, relapse risk, eligibility for HCT, comorbidities precluding transplant, and uncontrolled illness or social situations that could limit compliance with treatment. The supplied document discusses relapsed/refractory acute lymphoblastic leukemia (ALL) management in adolescents and young adults (AYAs), but it does not report United States population-level proportions advancing from first-line to subsequent lines of therapy, nor quantitative line-to-line attrition rates through 2026-09-21. The document does identify factors associated with relapse/refractory disease and treatment progression, stating that AYAs with relapsed/refractory ALL “experience greater treatment resistance” and “higher rates of toxicity.” It also discusses treatment sequencing considerations and consolidation decisions after relapse, including use of “blinatumomab,” “inotuzumab,” “CAR T-cell therapy,” and “allo-HSCT,” with treatment choice based on “individual patient assessment, burden of disease, and candidacy for future consolidative therapy.” Mortality-related attrition, demographic drivers beyond the AYA population, discontinuation patterns, and quantitative transition rates between therapy lines are not provided in the document. The supplied document reports induction treatment response and relapse information for adult acute lymphoblastic leukemia (ALL), but it does not provide explicit proportions of patients advancing from first-line to second-line or later lines of therapy through 2026-09-21 in United States populations. The document states that "Current multiagent induction regimens result in complete response rates that range from 60% to 90%" and also notes that "Responses were short lived, with most of these patients experiencing disease relapse at a median of 58 days after the start of therapy." Treatment-related and disease-related attrition factors described include relapse after therapy, short remission duration, and consideration of allogeneic bone marrow transplant because "remissions are generally short with conventional ALL chemotherapy clinical trials." No demographic drivers, mortality-related attrition proportions, or treatment discontinuation transition rates between therapy lines are reported in the provided material. The supplied document discusses management of relapsed/refractory acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs), but it does not report proportions of U.S. ALL patients advancing from first-line to later lines of therapy, nor quantitative line-to-line attrition rates through 2026-09-21. The document does describe factors associated with treatment challenges and decision-making in later-line therapy, stating that AYAs with relapsed/refractory ALL “experience greater treatment resistance” and “higher rates of toxicity,” and that treatment selection should consider “individual patient assessment, burden of disease, and candidacy for future consolidative therapy including allo-HSCT.” Mortality-related attrition, treatment discontinuation patterns, and demographic predictors of transition between therapy lines are not reported in the supplied evidence. The supplied documents do not report proportions of United States acute lymphoblastic leukemia patients who advance from first-line to second-line or later therapies, nor do they quantify attrition between lines of therapy. The documents do mention factors associated with outcomes and treatment decisions, including that survival rates “can vary depending on age, disease subtype, genetic features, and response to treatment,” and that newer adult ALL approaches are “less chemotherapy-intensive” with attention to “MRD risk stratification and transplant decision-making.” Mortality-related information is limited to population survival estimates, including a reported “5-year relative survival of 72.6%” in the United States and lower survival in adults compared with children.

National Cancer Institute (NCI)American Society of HematologyNational Cancer InstituteBlood advancesOpen web